Blog | Veristat, The Science-First CRO

Gain the latest insights and trends in clinical trials, patient recruitment, data analysis, adaptive design, regulatory submissions and approvals.

Sign Up Today

1 min read

Migration of Data Between EDCs

Factors such as ongoing industry consolidation, continual regulatory change, rapid technology evolution, and unending cost-cutting are causing organizations to consider replacing or upgrading their existing Electronic Data Capture (EDC) solution.

READ MORE

1 min read

Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial

Learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas of this full-service phase II cancer trial. Collaborative efforts led to the sponsor decided not to close the Phase II study upon the...

READ MORE

2 min read

How does Real-World Evidence Impact Medicinal Product Development in Europe?

Explore the growing role of Real-World Evidence (RWE) in the regulatory decision-making process for medicinal products in Europe. Learn how RWE is reshaping the development landscape, its potential benefits, and the challenges associated with its...

READ MORE

5 min read

Regulatory Guidance Monthly Review - May 2023

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development...

READ MORE

1 min read

The Rise of Decentralized Clinical Trials: Transforming Research Through Technology and Patient-Centricity

Learn how decentralized clinical trials (DCTs) are reshaping the clinical research landscape. Explore the insights shared by Shaheen Limbada, EVP of Innovation and Strategy at Veristat as he discusses the lessons learned from the pandemic, the role of...

READ MORE

Apples to Apples: Playing the Comparability Game in Biotherapeutics Development

Comparability studies are a significant issue for those working in biotherapeutics development, as undetected product changes are considered high risk.

READ MORE

1 min read

Understanding FDA's Project Optimus

Project Optimus is an initiative from the FDA Oncology Center of Excellence led by Drs. Mirat Shah and Atik Rahman.The goal of the initiative is to educate, innovate, and collaborate with the oncology community- including companies, academia,...

READ MORE

4 min read

Regulatory Guidance Monthly Review - April 2023

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development...

READ MORE

Regulatory Considerations for Biosimilars Development in the U.S.

The development of biosimilar products in the U.S. has progressed since the regulatory pathway was established as part of the Affordable Care Act. Since then, the number of active biosimilar development programs has risen steadily. The market for these...

READ MORE

Dedicated Regulatory Project Management

Drug developers hire regulatory consultants and CROs to help navigate the complex regulatory agency requirements and interactions throughout the development lifecycle. While most Sponsors understand the role of a Regulatory Strategist, fewer have...

READ MORE